Novartis Korea to reach the final agreement on Glivec's insurance price

Published: 2002-07-02 07:00:00

Updated: 2002-07-02 07:00:00

Novartis Korea said it will endeavor to reach a final pricing agreement of a novel anticancer therapy 'Glivec' with the Ministry of Health and Welfare (MOHW) based on the domestic insurance calculation criteria, in line with the delayed decision on the ceiling price of Glivec in the National Heal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK